Neurocrine Biosciences (NBIX) 13.84 $NBIX
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Thu May 08, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas.
Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics
PR Newswire - Thu May 08, 8:10AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.23% higher at 668.01, and the index has advanced 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on IRWD, NBIX, RIGL and SGEN can be downloaded upon signing up at:
Polycystic Ovarian Syndrome - Pipeline Review, H1 2014: 6 Company Profiles and 11 Drugs Profiled
M2 - Thu May 08, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/43d5b3/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - AstraZeneca PLC - Euroscreen S.A. - Neurocrine Biosciences, Inc. - Merck KGaA - EffRx Pharmaceuticals S.A. - Crinetics Pharmaceuticals, Inc. Drug Profiles: - choriogonadotropin alfa - doxycycline - AZD-4901 - ESN-364 - GnRH Antagonists - metformin hydrochloride - Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - Kisspeptin Peptide Antagonists - Metabolic Syndrome Program - KISS-1R Antagonist For Polycystic Ovarian Syndrome - Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/43d5b3/polycystic
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014: 5 Company and 8 Drugs Profiled
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mj5lmk/uterine_leiomyoma) has announced the addition of the "Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Neurocrine Biosciences, Inc. - Novartis AG - Dongkook Pharmaceutical Co., Ltd. - HRA Pharma, SA - Evestra, Inc. Drug Profiles: - ulipristal acetate - LFA-102 - GnRH Antagonists - Gonadotropin-Releasing Hormone Antagonists - EVE-104 - EC-304 - triptorelin pamoate biosimilar - Non-Steroidal Progesterone Agonist For more information visit http://www.researchandmarkets.com/research/mj..._leiomyoma
Neurocrine Biosciences to Present at Deutsche Bank's 39th Annual Health Care Conference
PR Newswire - Thu May 01, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 39th Annual Health Care Conference in Boston.
Neurocrine Biosciences announces reduced net loss of USD11.8m in Q1 2014
M2 - Thu May 01, 5:47AM CDT
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) disclosed on Wednesday its net loss of USD11.8m (USD0.17 loss per share) for the first quarter of 2014.
Neurocrine Biosciences Reports First Quarter 2014 Results
PR Newswire - Wed Apr 30, 3:01PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2014. For the first quarter of 2014, the Company reported a net loss of $11.8 million, or $0.17 loss per share, compared to a net loss of $12.1 million, or $0.18 loss per share, for the same period in 2013.
Will These 3 Drugs Keep AbbVie's Future Bright After Humira?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
AbbVie has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its...
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2014 Financial Results
PR Newswire - Fri Apr 25, 2:30PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2014 financial results after the Nasdaq market closes on Wednesday, April 30, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, April 30, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Critical Alerts For Goldman Sachs, JC Penney, Apache, PepsiCo, and Neurocrine Biosciences Released By InvestorsObserver
PR Newswire - Tue Apr 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GS, JCP, APA, PEP, and NBIX.
Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
Commit To Purchase Neurocrine Biosciences At $11, Earn 23.9% Annualized Using Options
at The Street - Mon Apr 07, 10:45AM CDT
Investors eyeing a purchase of Neurocrine Biosciences, Inc. stock, but tentative about paying the going market price of $14.27/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Neurocrine Biosciences To Present At The 26th Annual Roth Conference
PR Newswire - Tue Mar 04, 1:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
Neurocrine Biosciences prices public offering at USD17.75 per share
M2 - Thu Feb 27, 5:17AM CST
US-based drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Wednesday that it has priced its public offering of 8m shares of its common stock at USD17.75 per share.
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Wed Feb 26, 8:12PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire - Wed Feb 26, 5:00AM CST
Digirad Corporation (Nasdaq
RAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million.
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Thu May 08, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas.
Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics
PR Newswire - Thu May 08, 8:10AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.23% higher at 668.01, and the index has advanced 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on IRWD, NBIX, RIGL and SGEN can be downloaded upon signing up at:
Polycystic Ovarian Syndrome - Pipeline Review, H1 2014: 6 Company Profiles and 11 Drugs Profiled
M2 - Thu May 08, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/43d5b3/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - AstraZeneca PLC - Euroscreen S.A. - Neurocrine Biosciences, Inc. - Merck KGaA - EffRx Pharmaceuticals S.A. - Crinetics Pharmaceuticals, Inc. Drug Profiles: - choriogonadotropin alfa - doxycycline - AZD-4901 - ESN-364 - GnRH Antagonists - metformin hydrochloride - Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - Kisspeptin Peptide Antagonists - Metabolic Syndrome Program - KISS-1R Antagonist For Polycystic Ovarian Syndrome - Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/43d5b3/polycystic
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014: 5 Company and 8 Drugs Profiled
M2 - Wed May 07, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mj5lmk/uterine_leiomyoma) has announced the addition of the "Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Neurocrine Biosciences, Inc. - Novartis AG - Dongkook Pharmaceutical Co., Ltd. - HRA Pharma, SA - Evestra, Inc. Drug Profiles: - ulipristal acetate - LFA-102 - GnRH Antagonists - Gonadotropin-Releasing Hormone Antagonists - EVE-104 - EC-304 - triptorelin pamoate biosimilar - Non-Steroidal Progesterone Agonist For more information visit http://www.researchandmarkets.com/research/mj..._leiomyoma
Neurocrine Biosciences to Present at Deutsche Bank's 39th Annual Health Care Conference
PR Newswire - Thu May 01, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 39th Annual Health Care Conference in Boston.
Neurocrine Biosciences announces reduced net loss of USD11.8m in Q1 2014
M2 - Thu May 01, 5:47AM CDT
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) disclosed on Wednesday its net loss of USD11.8m (USD0.17 loss per share) for the first quarter of 2014.
Neurocrine Biosciences Reports First Quarter 2014 Results
PR Newswire - Wed Apr 30, 3:01PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2014. For the first quarter of 2014, the Company reported a net loss of $11.8 million, or $0.17 loss per share, compared to a net loss of $12.1 million, or $0.18 loss per share, for the same period in 2013.
Will These 3 Drugs Keep AbbVie's Future Bright After Humira?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
AbbVie has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its...
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2014 Financial Results
PR Newswire - Fri Apr 25, 2:30PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2014 financial results after the Nasdaq market closes on Wednesday, April 30, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, April 30, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Critical Alerts For Goldman Sachs, JC Penney, Apache, PepsiCo, and Neurocrine Biosciences Released By InvestorsObserver
PR Newswire - Tue Apr 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GS, JCP, APA, PEP, and NBIX.
Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
Commit To Purchase Neurocrine Biosciences At $11, Earn 23.9% Annualized Using Options
at The Street - Mon Apr 07, 10:45AM CDT
Investors eyeing a purchase of Neurocrine Biosciences, Inc. stock, but tentative about paying the going market price of $14.27/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Neurocrine Biosciences To Present At The 26th Annual Roth Conference
PR Newswire - Tue Mar 04, 1:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
Neurocrine Biosciences prices public offering at USD17.75 per share
M2 - Thu Feb 27, 5:17AM CST
US-based drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Wednesday that it has priced its public offering of 8m shares of its common stock at USD17.75 per share.
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Wed Feb 26, 8:12PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire - Wed Feb 26, 5:00AM CST
Digirad Corporation (Nasdaq
RAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million. 
